These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22785086)

  • 41. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Chen KY; Rha SW; Li YJ; Poddar KL; Jin Z; Minami Y; Wang L; Kim EJ; Park CG; Seo HS; Oh DJ; Jeong MH; Ahn YK; Hong TJ; Kim YJ; Hur SH; Seong IW; Chae JK; Cho MC; Bae JH; Choi DH; Jang YS; Chae IH; Kim CJ; Yoon JH; Chung WS; Seung KB; Park SJ;
    Circulation; 2009 Jun; 119(25):3207-14. PubMed ID: 19528339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention.
    Porter A; Konstantino Y; Iakobishvili Z; Shachar L; Battler A; Hasdai D
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):56-61. PubMed ID: 16763985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
    Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA
    Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prehospitalization antiplatelet therapy and outcomes after saphenous vein graft intervention.
    Harskamp RE; Beijk MA; Damman P; Tijssen JG; Lopes RD; de Winter RJ
    Am J Cardiol; 2013 Jan; 111(2):153-8. PubMed ID: 23102882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting.
    Gasparovic H; Petricevic M; Kopjar T; Djuric Z; Svetina L; Biocina B
    Am J Cardiol; 2014 May; 113(10):1660-7. PubMed ID: 24666617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
    Geisler T; Kapp M; Göhring-Frischholz K; Daub K; Dösch C; Bigalke B; Langer H; Herdeg C; Gawaz M
    Heart; 2008 Jun; 94(6):743-7. PubMed ID: 17567647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.
    Li J; Jian Z; Huang L; Guo H; Huang J; Qian D; Fu W; Li A; Song Y
    Biomed Pharmacother; 2009 Sep; 63(8):608-12. PubMed ID: 19019624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
    Storey RF; Bliden KP; Patil SB; Karunakaran A; Ecob R; Butler K; Teng R; Wei C; Tantry US; Gurbel PA;
    J Am Coll Cardiol; 2010 Jul; 56(3):185-93. PubMed ID: 20620737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study.
    Feres F; Costa RA; Bhatt DL; Leon MB; Botelho RV; King SB; de Paula JE; Mangione JA; Salvadori D; Gusmão MO; Castello H; Nicolela E; Perin MA; Devito FS; Marin-Neto JA; Abizaid A
    Am Heart J; 2012 Dec; 164(6):810-6.e3. PubMed ID: 23194480
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal medical therapy and percutaneous coronary intervention for stable angina: why patients should 'be taking' and 'keep taking' the tablets.
    Mohee K; Wheatcroft SB
    J Clin Pharm Ther; 2014 Aug; 39(4):331-3. PubMed ID: 24754310
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adherence to dual antiplatelet therapy: can we do better?
    Yallapragada S; Siddiqui S; Gindi R; Shroff A
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1417-24. PubMed ID: 24138527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lower gastrointestinal bleeding in patients with coronary artery disease on antithrombotics and subsequent mortality risk.
    Patel P; Nigam N; Sengupta N
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1185-1191. PubMed ID: 29156506
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A text messaging intervention to promote medication adherence for patients with coronary heart disease: a randomized controlled trial.
    Park LG; Howie-Esquivel J; Chung ML; Dracup K
    Patient Educ Couns; 2014 Feb; 94(2):261-8. PubMed ID: 24321403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of cardiopulmonary exercise test on platelet function in patients with coronary artery diseases on antiplatelet therapy.
    Yin C; Wang Y; Mo C; Yue Z; Sun Y; Hu D
    BMC Cardiovasc Disord; 2022 Mar; 22(1):87. PubMed ID: 35246028
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Illness beliefs about heart disease and adherence to secondary prevention regimens.
    Stafford L; Jackson HJ; Berk M
    Psychosom Med; 2008 Oct; 70(8):942-8. PubMed ID: 18842739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.